EC Clinical and Medical Case Reports

Corticosteroids have shown a clear benefit in reducing mortality for patients with severe COVID19, nonetheless, secondary infections have been reported with their use. In this paper, we present five cases of Colombian patients who developed invasive fungal infections by Trichosporon asahii. The patients had COVID-19 pneumonia, they were treated with corticosteroids and exposed to broad-spectrum antibiotics. The organism’s identification was achieved by MALDI-TOF, microscopy and culture. The patients were treated with itraconazole and amphotericin B deoxycholate. Four out of five patients died.

Keywords: Trichosporon asahii; Covid-19; SARS-CoV-2; Opportunistic Infections

1. Gavriatopoulou M., et al. “Emerging treatment strategies for COVID-19 infection”. Clinical and Experimental Medicine2 (2021): 167-179.
2. Panovska-Stavridis I., et al. “Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021)”. Pril1 (2021): 5-18.
3. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC., et al. “Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis”. The Journal of the American Medical Association13 (2020): 1330-1341.
4. Attaway AH., et al. “Severe covid-19 pneumonia: pathogenesis and clinical management”. British Medical Journal 372 (2021): n436.
5. Stockman LJ., et al. “SARS: systematic review of treatment effects”. PLOS Medicine 23 (2006): e343.
6. Shafran N., et al. “Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients”. Scientific Reports 11 (2021): 12703.
7. Salehi M., et al. “Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from Iran”. Mycopathologia4 (2020): 607-611.
8. Ramaswami A., et al. “COVID-19 associated Mucormycosis presenting to the emergency department – an observational study of 70 patients”. QJM: An International Journal of Medicine (2021).
9. Ghanem H and Sivasubramanian G. “Cryptococcus neoformans Meningoencephalitis in an immunocompetent patient after COVID-19 infection”. Case Reports in Infectious Diseases (2021): 5597473.
10. Segrelles-Calvo G., et al. “Trichosporon asahii as Cause of Nosocomial Pneumonia in Patient With COVID-19: A Triple Co-infection”. Archivos de Bronconeumología2 (2021): 46-48.
11. Ali GA., et al. “Trichosporon asahii fungemia and COVID-19 coinfection: An emerging fungal pathogen; case report and review of the literature”. ID Cases 25 (2021): e01244.
12. Li H., et al. “Epidemiological study of Trichosporon asahii infections over the past 23 years”. Epidemiology and Infection 148 (2020): e169.
13. Khan ID., et al. “Trichosporon asahii urinary tract infection in immunocompetent patients”. Medical Journal Armed Forces India4 (2015): 373-376.
14. Sood S., et al. “Urinary tract infection by Trichosporon asahii”. Indian Journal of Medical Microbiology4 (2006): 294-296.
15. Kumar S., et al. “A Rare Case of Nosocomial Urinary Tract Infection due to Trichosporon asahii”. Journal of Global Infectious Diseases3 (2011): 309-310.
16. De Pauw B., et al. “Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group”. Clinical Infectious Diseases12 (2008): 1813-1821.
17. Donnelly JP., et al. “Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium”. Clinical Infectious Diseases6 (2020): 1367-1376.
18. Nobrega De Almeida J Jr., et al. “Trichosporon asahii superinfections in critically ill COVID-19 patients overexposed to antimicrobials and corticosteroids”. Mycoses8 (2021): 817-822.
19. Toriumi Y., et al. “Antifungal pharmacodynamic characteristics of amphotericin B against Trichosporon asahii, using time-kill methodology”. Medical Microbiology and Immunology2 (2002): 89-93.
20. Kontoyiannis DP., et al. “Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome”. Scandinavian Journal of Infectious Diseases8 (2004): 564-569.
21. Suzuki K., et al. “Fatal Trichosporon fungemia in patients with hematologic malignancies”. European Journal of Haematology5 (2010): 441-447.
22. Krcmery V., et al. “Invasive yeast infections other than Candida spp. in acute leukaemia”. Journal of Hospital Infection3 (1999): 181-194.
23. Skiada A., et al. “Rare fungal infectious agents: a lurking enemy”. F1000Research 6 (2017): 1917.
24. Walsh TJ., et al. “Experimental Trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis”. The Journal of Infectious Diseases1 (1992): 121-133.
25. Arendrup MC., et al. “ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections”. Clinical Microbiology and Infection3 (2014): 76-98.
26. De Almeida Júnior JN and Hennequin C. “Invasive Trichosporon Infection: a Systematic Review on a Re-emerging Fungal Pathogen”. Frontiers in Microbiology 7 (2016): 1629.
27. Sugita T., et al. “Sequence analysis of the ribosomal DNA intergenic spacer 1 regions of Trichosporon species”. Journal of Clinical Microbiology5 (2002): 1826-1830.
28. De Almeida Júnior JN., et al. “Usefulness of matrix-assisted laser desorption ionisation-time-of-flight mass spectrometry for identifying clinical Trichosporon isolates”. Clinical Microbiology and Infection8 (2014): 784-790.